CA2112239A1 - Enantiomeric Hydroxylated Xanthine Compounds - Google Patents

Enantiomeric Hydroxylated Xanthine Compounds

Info

Publication number
CA2112239A1
CA2112239A1 CA 2112239 CA2112239A CA2112239A1 CA 2112239 A1 CA2112239 A1 CA 2112239A1 CA 2112239 CA2112239 CA 2112239 CA 2112239 A CA2112239 A CA 2112239A CA 2112239 A1 CA2112239 A1 CA 2112239A1
Authority
CA
Canada
Prior art keywords
compounds
enantiomeric
xanthine compounds
hydroxylated
hydroxylated xanthine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA 2112239
Other languages
French (fr)
Other versions
CA2112239C (en
Inventor
James A. Bianco
Paul Woodson
David Porubek
Jack Singer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CTI Biopharma Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2112239A1 publication Critical patent/CA2112239A1/en
Application granted granted Critical
Publication of CA2112239C publication Critical patent/CA2112239C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/10—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 3 and 7, e.g. theobromine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Abstract

There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an omega -1 alcohol of a straight chain alkyl (C5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in modulating cellular response to external or in situ primary stimuli, as well as to specific modes of administration of such compounds in effective amounts.
CA002112239A 1992-03-04 1993-03-01 Enantiomeric hydroxylated xanthine compounds Expired - Fee Related CA2112239C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US84635492A 1992-03-04 1992-03-04
US07/846,354 1992-03-04
US92666592A 1992-08-07 1992-08-07
US07/926,665 1992-08-07
PCT/US1993/002304 WO1993017684A2 (en) 1992-03-04 1993-03-01 Enantiomeric hydroxylated xanthine compounds

Publications (2)

Publication Number Publication Date
CA2112239A1 true CA2112239A1 (en) 1993-09-16
CA2112239C CA2112239C (en) 2000-05-09

Family

ID=27126630

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002112239A Expired - Fee Related CA2112239C (en) 1992-03-04 1993-03-01 Enantiomeric hydroxylated xanthine compounds

Country Status (17)

Country Link
US (8) US5652243A (en)
EP (1) EP0584347B1 (en)
JP (4) JP2753395B2 (en)
KR (1) KR950700066A (en)
CN (1) CN1040646C (en)
AT (1) ATE230990T1 (en)
AU (1) AU669702B2 (en)
CA (1) CA2112239C (en)
CZ (1) CZ212394A3 (en)
DE (1) DE69332634T2 (en)
DK (1) DK0584347T3 (en)
ES (1) ES2191013T3 (en)
IL (1) IL104943A (en)
NO (1) NO943263L (en)
NZ (1) NZ247038A (en)
PT (1) PT584347E (en)
WO (1) WO1993017684A2 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693105B1 (en) * 1992-11-16 2004-02-17 Cell Therapeutics, Inc. Hydroxyl-containing compounds
US5795897A (en) * 1992-11-18 1998-08-18 Cell Therapeutics, Inc. Oxohexyl methylxanthine compounds
EP0728003A1 (en) 1993-11-12 1996-08-28 Cell Therapeutics, Inc. Method for preventing tissue injury from hypoxia
CA2192470A1 (en) * 1994-01-14 1995-07-20 Paul A. Brown Method for treating diseases mediated by cellular proliferation in response to pdgf, egf, fgf and vegf
US5807861A (en) * 1994-03-24 1998-09-15 Cell Therapeutics, Inc. Amine substituted xanthinyl compounds
ATE226200T1 (en) * 1994-05-16 2002-11-15 Cell Therapeutics Inc ASYMMETRIC SYNTHESIS OF CHIRAL SECONDARY ALCOHOLS
US5643893A (en) * 1994-06-22 1997-07-01 Macronex, Inc. N-substituted-(Dihydroxyboryl)alkyl purine, indole and pyrimidine derivatives, useful as inhibitors of inflammatory cytokines
DE4430127A1 (en) * 1994-08-25 1996-03-14 Hoechst Ag Combination preparation containing cyclosporin A or FK506 and a xanthine derivative
DE4430128A1 (en) * 1994-08-25 1996-02-29 Hoechst Ag Combination preparation with immunosuppressive, cardiovascular and cerebral effects
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
US6136964A (en) * 1996-03-19 2000-10-24 Cell Therapeutics, Inc. Mammalian lysophosphatidic acid acyltransferase
CA2291516A1 (en) * 1997-05-27 1998-12-03 Cell Therapeutics, Inc. Mammalian lysophosphatidic acid acyltransferase
JP2001519381A (en) * 1997-10-10 2001-10-23 インペリアル・カレッジ・イノベイションズ・リミテッド Use of CSAID ™ compounds for management of uterine contractions
US6111329A (en) * 1999-03-29 2000-08-29 Graham; Gregory S. Armature for an electromotive device
WO2001022950A2 (en) * 1999-09-24 2001-04-05 Shire Biochem Inc. Diosolane nucleoside analogs for the treatment or prevention of viral infection
FR2804867B1 (en) * 2000-02-15 2002-09-20 Hoechst Marion Roussel Inc APPLICATION OF XANTHINE DERIVATIVES FOR THE PREPARATION OF A MEDICAMENT FOR THE PREVENTION OR TREATMENT OF OSTEOPOROSIS
US20040243097A1 (en) * 2000-05-12 2004-12-02 Robert Falotico Antiproliferative drug and delivery device
US6776796B2 (en) 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
US8236048B2 (en) 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
JP5100951B2 (en) 2000-09-29 2012-12-19 コーディス・コーポレイション Coated medical device
US20020111590A1 (en) * 2000-09-29 2002-08-15 Davila Luis A. Medical devices, drug coatings and methods for maintaining the drug coatings thereon
US20020051730A1 (en) * 2000-09-29 2002-05-02 Stanko Bodnar Coated medical devices and sterilization thereof
IL159512A0 (en) 2001-06-26 2004-06-01 Abgenix Inc Antibodies to opgl
EP1414517A4 (en) * 2001-06-26 2008-02-06 Photomed Technologies Inc Multiple wavelength illuminator
US7195640B2 (en) * 2001-09-25 2007-03-27 Cordis Corporation Coated medical devices for the treatment of vulnerable plaque
US7108701B2 (en) * 2001-09-28 2006-09-19 Ethicon, Inc. Drug releasing anastomosis devices and methods for treating anastomotic sites
US20030065377A1 (en) * 2001-09-28 2003-04-03 Davila Luis A. Coated medical devices
NZ593428A (en) 2002-09-06 2013-01-25 Amgen Inc Therapeutic human anti-il-1r1 monoclonal antibody
WO2004060911A2 (en) * 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
AU2005212816C1 (en) 2004-02-14 2010-03-04 Glaxosmithkline Llc Novel compounds
EP1841448A2 (en) * 2004-12-30 2007-10-10 Diakine Therapeutics, Inc. Pharmaceutical compositions and methods for restoring beta-cell mass and function
PE20070405A1 (en) 2005-08-10 2007-05-06 Smithkline Beecham Corp XANTHINE-DERIVED COMPOUNDS AS AGONISTS OF THE NICOTINIC ACID RECEPTOR HM74A
US20080059313A1 (en) * 2006-08-30 2008-03-06 Oblong John E Hair care compositions, methods, and articles of commerce that can increase the appearance of thicker and fuller hair
CN104825341A (en) * 2008-02-29 2015-08-12 宝洁公司 Hair care compositions and methods for increasing hair diameter
US9133062B2 (en) 2012-11-21 2015-09-15 Corning Incorporated Method of firing cordierite bodies
MX2015015676A (en) 2013-05-16 2016-03-04 Procter & Gamble Hair thickening compositions and methods of use.
CN103880861B (en) * 2014-02-21 2016-02-03 温州医科大学 A kind of 4,6-dimethyl-oxazoles also [5,4-d] pyrimidine-5 acting on FGF receptor, 7(4H, 6H)-derovatives
MX2017004655A (en) * 2014-10-09 2018-03-27 Guangdong Zhongsheng Pharmaceutical Co Ltd Hydroxyl purine compounds and applications thereof.
CN111233863B (en) * 2014-10-09 2022-10-25 广东众生睿创生物科技有限公司 Hydroxyl purine compound and application thereof
EP3369733B1 (en) 2015-10-29 2020-01-15 Guangdong Raynovent Biotech Co., Ltd. Crystal form of 4h-pyrazolo[1,5- ]benzoimidazole compound, preparation method therefor and intermediate thereof
WO2020035482A1 (en) 2018-08-13 2020-02-20 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
WO2023222565A1 (en) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3422107A (en) * 1964-09-05 1969-01-14 Albert Ag Chem Werke Certain oxoalkyldimethylxanthines and a process for the preparation thereof
US3373433A (en) * 1964-12-16 1968-03-12 Sylvania Electric Prod Dual linear/circular polarization spiral antenna
US4576947A (en) * 1967-12-16 1986-03-18 Hoechst Aktiengesellschaft Pharmaceutical compositions
US4515795A (en) * 1968-11-25 1985-05-07 Hoechst Aktiengesellschaft Pharmaceutical compositions
US4525309A (en) * 1983-03-15 1985-06-25 Washington State University Research Foundation, Inc. Lewis acid catalysis of the homologation of boronic esters with haloalkylmetal reagents
US4636507A (en) * 1984-04-30 1987-01-13 Hoechst-Roussel Pharmaceuticals Inc. Host defense mechanism enhancement
DE3525801A1 (en) * 1985-07-19 1987-01-22 Hoechst Ag TERTIA HYDROXYALKYLXANTHINE, METHOD FOR THE PRODUCTION THEREOF, THE MEDICINAL PRODUCT CONTAINING IT AND THEIR USE
US5272153A (en) * 1986-12-31 1993-12-21 Hoechst-Roussel Pharmaceuticals, Inc. Method of inhibiting the activity of leukocyte derived cytokines
US4965271A (en) * 1986-12-31 1990-10-23 Hoechst Roussel Pharmaceuticals, Inc. Method of inhibiting the activity of leukocyte derived cytokines
US5096906A (en) * 1986-12-31 1992-03-17 University Of Virginia Alumni Patents Foundation Method of inhibiting the activity of leukocyte derived cytokines
DE3817955A1 (en) * 1988-05-27 1989-11-30 Hoechst Ag MEDICINAL PRODUCT CONTAINING TNF INHIBITOR
DE3942872A1 (en) * 1989-12-23 1991-06-27 Hoechst Ag METHOD FOR THE ENANTIOSELECTIVE PRESENTATION OF ((OMEGA) -1) -HYDROXYALKYLXANTHINES
DE3942871A1 (en) * 1989-12-23 1991-06-27 Hoechst Ag R - (-) - 1- (5-HYDROXYHEXYL) -3-METHYL-7-PROPYLXANTHINE, METHOD OF ITS PREPARATION AND MEDICAMENTS CONTAINING THIS COMPOUND
US5112827A (en) * 1990-05-18 1992-05-12 Board Of Regents, The University Of Texas System Drug to reverse fatty liver and atheromatous lesions
US5039666A (en) * 1990-10-30 1991-08-13 Hoechst-Roussel Pharmaceuticals Inc. Aminoglycoside composition having substantially reduced nephrotoxicity induced by the aminoglycoside
AU664189B2 (en) * 1991-05-24 1995-11-09 Fred Hutchinson Cancer Research Center Modulation of cellular response to external stimuli
MX9203323A (en) * 1991-07-11 1994-07-29 Hoechst Ag THE USE OF XANTHINE DERIVATIVES FOR THE TREATMENT OF SECONDARY INJURIES OF THE NERVOUS CELLS AND FUNCTIONAL DISORDERS AFTER CRANIAL-BRAIN TRAUMA.

Also Published As

Publication number Publication date
DE69332634T2 (en) 2003-05-08
JP2002087961A (en) 2002-03-27
IL104943A0 (en) 1993-07-08
US5612349A (en) 1997-03-18
WO1993017684A2 (en) 1993-09-16
US5629315A (en) 1997-05-13
US5621102A (en) 1997-04-15
US5792772A (en) 1998-08-11
DK0584347T3 (en) 2003-02-24
JPH06509584A (en) 1994-10-27
PT584347E (en) 2003-06-30
EP0584347A4 (en) 1995-04-26
WO1993017684A3 (en) 1993-11-25
CN1085557A (en) 1994-04-20
EP0584347A1 (en) 1994-03-02
NO943263L (en) 1994-11-02
ATE230990T1 (en) 2003-02-15
EP0584347B1 (en) 2003-01-15
US5652243A (en) 1997-07-29
KR950700066A (en) 1995-01-16
JPH08259565A (en) 1996-10-08
JP2753395B2 (en) 1998-05-20
NZ247038A (en) 1995-02-24
US5965564A (en) 1999-10-12
CA2112239C (en) 2000-05-09
CZ212394A3 (en) 1995-09-13
NO943263D0 (en) 1994-09-02
US5620984A (en) 1997-04-15
JP2004002467A (en) 2004-01-08
AU3919093A (en) 1993-10-05
DE69332634D1 (en) 2003-02-20
US5739138A (en) 1998-04-14
IL104943A (en) 1998-12-27
CN1040646C (en) 1998-11-11
AU669702B2 (en) 1996-06-20
ES2191013T3 (en) 2003-09-01

Similar Documents

Publication Publication Date Title
CA2112239A1 (en) Enantiomeric Hydroxylated Xanthine Compounds
NZ240230A (en) Mercaptoacetylamide derivatives; preparation, use and pharmaceutical compositions thereof
NZ236589A (en) A-nor-steroid-3-carboxylic acid derivatives and pharmaceutical compositions
AU589378B2 (en) Pharmaceutical compositions containing inositol triphosphates
MY115339A (en) Compositions containing micronized nebivolol
ES378823A1 (en) Aminobenzocycloalkane compounds
IL74497A (en) Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
TW225534B (en)
AU2524692A (en) Novel 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ace
IL114599A0 (en) Substituted pyrimidine compounds their preparation and pharmaceutical compositions containing them
MY105328A (en) Blocking agents of edrf effect or formation for the treatment of shock.
IL107870A0 (en) Pharmaceutical compositions having antidepressant activity comprising pramipexol
MY117090A (en) Substituted benzamidines, their preparation and their use as pharmaceutical compounds
ES2004985A6 (en) 1-(4-Aminophenyl)-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepine and acid addition salts thereof same
CA2027351A1 (en) Emulsion of lipid containing a prostaglandin analogue
AU6319480A (en) 2-hydroxyalkyl-3,4,5-trihydroxypiperidines
EP0194093A3 (en) Substituted heterocyclic acrylic acids and esters, their preparation and pharmaceutical compositions containing them
MD502G2 (en) New adenozine derivatives, methods of obtainitg thereof, farmaceutical compositions on the base thereof
ATE66673T1 (en) 2-PYRROLIDONE DERIVATIVES, METHOD OF PREPARATION, PHARMACEUTICAL COMPOSITIONS AND APPLICATION.
EP0186023A3 (en) Biliary acid derivatives, process for their preparation and pharmaceutical compositions containing them
ES2039292T3 (en) DERIVATIVES OF PYRANOBENZOXADIAZOLE, PREPARATION OF THE SAME, USE AND COMPOUNDS THAT INCLUDE THEM.
AU558461B2 (en) Carbamyloxybenzhyrol derivatives
MX9204815A (en) HEXAHIDROBENZO [F] QUINOLINONAS AND PHARMACEUTICAL FORMULATION THAT INCLUDES THEM.
BG99313A (en) 117-alkylketonesteroids as 5- -reductase inhibitors
MX9303392A (en) DERIVATIVES OF IMIDAZO BENZOXAZIN-1-ONA SUBSTITUTED AND PROCESS FOR ITS PREPARATION.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed